Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Adult Annular Pancreas Presenting With Gastric Outlet Obstruction Following Semaglutide Initiation: A Case Report.

Gamaleldin F, Raje M, John SK

Cureus27 Jun 2026

PMID42523990 (opens in a new tab)PMCIDPMC13408417 (opens in a new tab)DOI10.7759/cureus.111636 (opens in a new tab)PepBankPUB-42523990
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Annular pancreas is a rare congenital anomaly that may remain clinically silent until adulthood. Its symptoms can be masked or exacerbated by glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which delay gastric emptying. We report a 55-year-old male with type 2 diabetes who developed progressive postprandial vomiting and nine-kg weight loss following semaglutide initiation. Imaging revealed a partial annular pancreas causing second-part duodenal stenosis without malignancy. Symptoms persisted despite semaglutide discontinuation, supporting a fixed mechanical obstruction as the primary aetiology. The patient underwent successful Roux-en-Y gastrojejunostomy and cholecystectomy; histopathology confirmed benign fibrotic pancreatic tissue. At follow-up, the patient was symptom-free with nutritional recovery. This case emphasises that severe gastrointestinal symptoms in patients on GLP-1 RAs should prompt evaluation for structural pathology rather than being attributed solely to medication side effects, ensuring timely surgical intervention.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 55-year-old man with type 2 diabetes, progressive postprandial vomiting and nine-kg weight loss followed semaglutide initiation.

    In plain wordsIn one man with type 2 diabetes, vomiting and nine-kg weight loss began after starting semaglutide; the authors found a structural pancreas problem.

    Peptide
    Semaglutide
    Outcome
    Not applicablePostprandial vomiting and weight loss after semaglutide initiation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report a 55-year-old male with type 2 diabetes who developed progressive postprandial vomiting and nine-kg weight loss following semaglutide initiation.
  2. 02HumanCase report or seriesSafety outcome

    In this patient, symptoms persisted despite semaglutide discontinuation, supporting a fixed mechanical obstruction from annular pancreas as the main cause.

    In plain wordsIn this one patient, symptoms continued after semaglutide was stopped, pointing to a structural blockage as the main cause.

    Peptide
    Semaglutide
    Outcome
    No significant changeSymptoms after semaglutide discontinuation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Symptoms persisted despite semaglutide discontinuation, supporting a fixed mechanical obstruction as the primary aetiology.
    1 context sentence
    Summary · context
    Imaging revealed a partial annular pancreas causing second-part duodenal stenosis without malignancy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.